ScripUCB has become the latest Europe drugmaker to pledge major manufacturing investments in the US amid the pressure being put on the pharmaceutical sector by President Trump administration to move more d
ScripOne year after Biogen bought the CD38-targeting antibody felzartamab in its acquisition of Human Immunology Biosciences (HI-Bio), the company has initiated two Phase III studies in two different areas
ScripThe biggest upcoming catalysts for NewAmsterdam Pharma’s CETP inhibitor obicetrapib as a means for lowering low-density lipoprotein cholesterol (LDL-C) are regulatory submissions later this year based